ERBB2 and neoplasm: The ASCO/CAP Group 2 patients (n = 46) showed pCR in 26% of tumours compared with 18% of those in Group 1 and 8% of those in Group 3, respectively (both currently categorised as HER2 positive in the UK) (Table 1).